Expression and purification of His-tagged HPV16 E7 protein active in pRb binding

Protein Expression and Purification

Volumn 48, Issue 2, 2006, Pages 281-291

  Mirecka, Ewa A ^a   Rudolph, Rainer ^a   Hey, Thomas ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Scil Proteins GmbH   (Germany)

Author keywords

BIAcore; E7; ELISA; Hexahistidine tag; Human papillomavirus; pRb; ProteoExpert; SPR

Indexed keywords

HISTIDINE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; RECOMBINANT PROTEIN; RETINOBLASTOMA PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BIOSYNTHESIS; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR CLONING; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

AMINO ACID SEQUENCE; BASE SEQUENCE; CLONING, MOLECULAR; ESCHERICHIA COLI; GENE EXPRESSION; HISTIDINE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; RECOMBINANT PROTEINS; RETINOBLASTOMA PROTEIN;

ESCHERICHIA COLI; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 33746218398     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2006.04.017     Document Type: Article

References (59)

1. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 49 (1989) 4677-4681
2. Motoyama S., Ladines-Llave C.A., Luis Villanueva S., and Maruo T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J. Med. Sci. 50 (2004) 9-19
3. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92 (2000) 690-698
4. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., and Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8 (1989) 3905-3910
5. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., and Zacny V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20 (2001) 7888-7898
6. Helt A.M., and Galloway D.A. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24 (2003) 159-169
7. Munger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., and Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8 (1989) 4099-4105
8. Dyson N., Howley P.M., Munger K., and Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 (1989) 934-937
9. Phillips A.C., and Vousden K.H. Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein, TBP. J. Gen. Virol. 78 Pt 4 (1997) 905-909
10. Zwerschke W., Mazurek S., Massimi P., Banks L., Eigenbrodt E., and Jansen-Durr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA 96 (1999) 1291-1296
11. Schilling B., De-Medina T., Syken J., Vidal M., and Munger K. A novel human DnaJ protein, hTid-1, a homolog of the Drosophila tumor suppressor protein Tid56, can interact with the human papillomavirus type 16 E7 oncoprotein. Virology 247 (1998) 74-85
12. Brehm A., Nielsen S.J., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., and Kouzarides T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 18 (1999) 2449-2458
13. Hsieh J.K., Yap D., O'Connor D.J., Fogal V., Fallis L., Chan F., Zhong S., and Lu X. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol. Cell Biol. 22 (2002) 78-93
14. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12 (1998) 2245-2262
15. Gonzalez S.L., Stremlau M., He X., Basile J.R., and Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 75 (2001) 7583-7591
16. Wang J., Sampath A., Raychaudhuri P., and Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 20 (2001) 4740-4749
17. Frolov M.V., and Dyson N.J. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J. Cell Sci. 117 (2004) 2173-2181
18. Ciccolini F., Di Pasquale G., Carlotti F., Crawford L., and Tommasino M. Functional studies of E7 proteins from different HPV types. Oncogene 9 (1994) 2633-2638
19. Heck D.V., Yee C.L., Howley P.M., and Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. USA 89 (1992) 4442-4446
20. Munger K., Yee C.L., Phelps W.C., Pietenpol J.A., Moses H.L., and Howley P.M. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65 (1991) 3943-3948
21. Xiao B., Spencer J., Clements A., Ali-Khan N., Mittnacht S., Broceno C., Burghammer M., Perrakis A., Marmorstein R., and Gamblin S.J. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc. Natl. Acad. Sci. USA 100 (2003) 2363-2368
22. Liu X., Clements A., Zhao K., and Marmorstein R. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. (2005)
23. Lee J.O., Russo A.A., and Pavletich N.P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391 (1998) 859-865
24. Barbosa M.S., Lowy D.R., and Schiller J.T. Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J. Virol. 63 (1989) 1404-1407
25. Phelps W.C., Munger K., Yee C.L., Barnes J.A., and Howley P.M. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol. 66 (1992) 2418-2427
26. Barbosa M.S., Edmonds C., Fisher C., Schiller J.T., Lowy D.R., and Vousden K.H. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 9 (1990) 153-160
27. Moran E., and Mathews M.B. Multiple functional domains in the adenovirus E1A gene. Cell 48 (1987) 177-178
28. Clemens K.E., Brent R., Gyuris J., and Munger K. Dimerization of the human papillomavirus E7 oncoprotein in vivo. Virology 214 (1995) 289-293
29. Jones R.E., Wegrzyn R.J., Patrick D.R., Balishin N.L., Vuocolo G.A., Riemen M.W., Defeo-Jones D., Garsky V.M., Heimbrook D.C., and Oliff A. Identification of HPV-16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein. J. Biol. Chem. 265 (1990) 12782-12785
30. Patrick D.R., Oliff A., and Heimbrook D.C. Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J. Biol. Chem. 269 (1994) 6842-6850
31. Zatsepina O., Braspenning J., Robberson D., Hajibagheri M.A., Blight K.J., Ely S., Hibma M., Spitkovsky D., Trendelenburg M., Crawford L., and Tommasino M. The human papillomavirus type 16 E7 protein is associated with the nucleolus in mammalian and yeast cells. Oncogene 14 (1997) 1137-1145
32. Smotkin D., and Wettstein F.O. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J. Virol. 61 (1987) 1686-1689
33. Firzlaff J.M., Galloway D.A., Eisenman R.N., and Luscher B. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol. 1 (1989) 44-53
34. Fernando G.J., Murray B., Zhou J., and Frazer I.H. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin. Exp. Immunol. 115 (1999) 397-403
35. Carter J.J., Yaegashi N., Jenison S.A., and Galloway D.A. Expression of human papillomavirus proteins in yeast Saccharomyces cerevisiae. Virology 182 (1991) 513-521
36. Zerfass K., Schulze A., Spitkovsky D., Friedman V., Henglein B., and Jansen-Durr P. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J. Virol. 69 (1995) 6389-6399
37. Chinami M., Sasaki S., Hachiya N., Yuge K., Ohsugi T., Maeda H., and Shingu M. Functional oligomerization of purified human papillomavirus types 16 and 6b E7 proteins expressed in Escherichia coli. J. Gen. Virol. 75 Pt 2 (1994) 277-281
38. Rawls J.A., Pusztai R., and Green M. Chemical synthesis of human papillomavirus type 16 E7 oncoprotein: autonomous protein domains for induction of cellular DNA synthesis and for trans activation. J. Virol. 64 (1990) 121-6129
39. Pahel G., Aulabaugh A., Short S.A., Barnes J.A., Painter G.R., Ray P., and Phelps W.C. Structural and functional characterization of the HPV16 E7 protein expressed in bacteria. J. Biol. Chem. 268 (1993) 26018-26025
40. Moro A., and Hernandez P. Bacterial expression and immunological detection of human papillomavirus type 16 E7 protein. Biochem. Biophys. Res. Commun. 226 (1996) 895-899
41. Braspenning J., Manetti R., Zumbach K., Meschede W., Gissmann L., and Tommasino M. A general purification protocol for E7 proteins from "high- and low-risk" human papillomavirus types expressed in the yeast Schizosaccharomyces pombe. Protein Expr. Purif. 10 (1997) 192-201
42. Stacey S.N., Ghosh A., Bartholomew J.S., Tindle R.W., Stern P.L., Mackett M., and Arrand J.R. Expression of human papillomavirus type 16 E7 protein by recombinant baculovirus and use for the detection of E7 antibodies in sera from cervical carcinoma patients. J. Med. Virol. 40 (1993) 14-21
43. Tommasino M., Contorni M., Scarlato V., Bugnoli M., Maundrell K., and Cavalieri F. Synthesis, phosphorylation, and nuclear localization of human papillomavirus E7 protein in Schizosaccharomyces pombe. Gene 93 (1990) 265-270
44. Park D.S., Selvey L.A., Kelsall S.R., and Frazer I.H. Human papillomavirus type 16 E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses. J. Virol. Methods 45 (1993) 303-318
45. Patrick D.R., Zhang K., Defeo-Jones D., Vuocolo G.R., Maigetter R.Z., Sardana M.K., Oliff A., and Heimbrook D.C. Characterization of functional HPV-16 E7 protein produced in Escherichia coli. J. Biol. Chem. 267 (1992) 6910-6915
46. Kasher M.S., Wakulchik M., Cook J.A., and Smith M.C. One-step purification of recombinant human papillomavirus type 16 E7 oncoprotein and its binding to the retinoblastoma gene product. Biotechniques 14 (1993) 630-641
47. Chinami M., Yuge K., Kawano K., and Shingu M. Refolding and purification of human papillomavirus type 16 E7-lacZ fusion protein expressed in Escherichia coli. Protein Expr. Purif. 2 (1991) 175-178
48. Alonso L.G., Garcia-Alai M.M., Nadra A.D., Lapena A.N., Almeida F.L., Gualfetti P., and Prat-Gay G.D. High-risk (HPV16) human papillomavirus E7 oncoprotein is highly stable and extended, with conformational transitions that could explain its multiple cellular binding partners. Biochemistry 41 (2002) 10510-10518
49. Sato H., Watanabe S., Furuno A., and Yoshiike K. Human papillomavirus type 16 E7 protein expressed in Escherichia coli and monkey COS-1 cells: immunofluorescence detection of the nuclear E7 protein. Virology 170 (1989) 311-315
50. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., and Wu T.C. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60 (2000) 1035-1042
51. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
52. Alonso L.G., Garcia-Alai M.M., Smal C., Centeno J.M., Iacono R., Castano E., Gualfetti P., and de Prat-Gay G. The HPV16 E7 viral oncoprotein self-assembles into defined spherical oligomers. Biochemistry 43 (2004) 3310-3317
53. Clements A., Johnston K., Mazzarelli J.M., Ricciardi R.P., and Marmorstein R. Oligomerization properties of the viral oncoproteins adenovirus E1A and human papillomavirus E7 and their complexes with the retinoblastoma protein. Biochemistry 39 (2000) 16033-16045
54. Imai Y., Matsushima Y., Sugimura T., and Terada M. Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. J. Virol. 65 (1991) 4966-4972
55. Choo K.B., Wang T.S., and Huang C.J. Analysis of relative binding affinity of E7-pRB of human papillomavirus 16 clinical variants using the yeast two-hybrid system. J. Med. Virol. 61 (2000) 298-302
56. Dong W.L., Caldeira S., Sehr P., Pawlita M., and Tommasino M. Determination of the binding affinity of different human papillomavirus E7 proteins for the tumour suppressor pRb by a plate-binding assay. J. Virol. Methods 98 (2001) 91-98
57. Hallez S., Simon P., Maudoux F., Doyen J., Noel J.C., Beliard A., Capelle X., Buxant F., Fayt I., Lagrost A.C., Hubert P., Gerday C., Burny A., Boniver J., Foidart J.M., Delvenne P., and Jacobs N. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol. Immunother. 53 (2004) 642-650
58. Nauenburg S., Zwerschke W., and Jansen-Durr P. Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein. FASEB J. 15 (2001) 592-594
59. Accardi L., Dona M.G., Di Bonito P., and Giorgi C. Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells. Int. J. Cancer (2005)